Evolving Technology Platforms in Pharma-Biotech

Evolving Technology Platforms in Pharma-Biotech

The continued development of new treatments associated with the demographic trends and public health considerations is essential. The biopharmaceutical industry is one of the most research intensive sectors in developed nations. Investments are more than USD 125 billion, especially in early stages development phases, including the processes of discovering and developing new medicines. Biopharmaceutical innovation has played a major role in the improvement of both length and quality of life during the past decade, considerably reducing the disease burden for individuals and the society. Groundbreaking advances in the scientific understanding of the underlying mechanisms of disease are paving the way for precision medicine for the upcoming years. Indeed, the promise of personalized medicine is becoming a reality generating notable improvements in human health and the potential to reduce the socioeconomic burden of disease. This research service (RS) depicts the current landscape of biopharmaceutical development, focusing on medicines that have progressed beyond early stage development and have recently entered clinical testing in human volunteers or first-in-human studies. The RS also includes:

R&D portfolio and budgetary analysis

Environmental analysis, depicting the key technical challenges, key business challenges, and emerging market needs

Industry best practices and strategic insights, measuring performance, assessment of partnerships and alliances and R&D pipeline by milestones

Strategic evaluation of R&D portfolio